Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
Open Access
- 19 January 2022
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 163, 108-118
- https://doi.org/10.1016/j.ejca.2021.12.024
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patientsMolecular and Clinical Oncology, 2015
- Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell CarcinomaClinical Cancer Research, 2015
- Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinomaAnnals of Oncology, 2015
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vesselsNature Communications, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to BiomarkersJournal of Clinical Oncology, 2013
- Angiotensin II Drives the Production of Tumor-Promoting MacrophagesImmunity, 2013
- Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examinationEuropean Journal of Cancer, 2011
- The renin–angiotensin system and cancer: old dog, new tricksNature Reviews Cancer, 2010
- The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.2001